Trial Profile
A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Pharmacodynamics; Registrational
- Sponsors Denovo Biopharma; Eli Lilly and Company
- 05 Oct 2021 this study has been completed in Spain ( global end of the trial 2012-10-12 ) as per European Clinical Trials Database record
- 29 Aug 2012 Status changed from active, no longer recruiting to discontinued, according to an Eli Lilly media release.
- 15 May 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.